Back to Results

Lucid Diagnostics Inc (LUCD)

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on detecting esophageal precancer and cancer in the United States. The company serves patients with gastroesophageal reflux disease, or GERD, who face an elevated risk of developing esophageal adenocarcinoma, a serious form of esophageal cancer. Its core offering is the EsoGuard Esophageal DNA Test, which is used with the EsoCheck Esophageal Cell Collection Device to obtain samples for testing. Lucid Diagnostics was incorporated in 2018 and is headquartered in New York, New York. It operates as a subsidiary of PAVmed Inc., and its common stock is listed on the NASDAQ exchange under the symbol LUCD.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-LUCD
$0.74
-5.8% Downside
Fair
$4
409.1% Upside
Bargain
Weak
0.0%
November 16, 2026
13.7x
27.6x
150 M
140.5 M
14.3%
73.7%
-12.0
72.6%
Valuation • Fair Value

Lucid Diagnostics Inc (NASDAQ-LUCD) Fair Value by Valuation Model

Review the available estimates for Lucid Diagnostics Inc (NASDAQ-LUCD), including EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$0.74

Estimated downside of 5.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

EPV Fair Value

$0.88

Earnings power value estimate.

Comps Fair Value

$0.72

Comparable-company valuation reference.

Analyst Price Target

$4

Analysts imply upside of 409.1%.

How to read these valuation models

Use the 5 available valuation references for Lucid Diagnostics Inc (NASDAQ-LUCD) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Lucid Diagnostics Inc (NASDAQ-LUCD)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

5.445 M

Current operating scale indicator.

Revenue Forecast

6.2 M

Forward revenue estimate.

EBITDA

-49.808 M

Current operating profitability reference.

EBITDA Forecast

-47.55 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Lucid Diagnostics Inc (NASDAQ-LUCD) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Lucid Diagnostics Inc (NASDAQ-LUCD)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.65

No elevated caution signal from this screen.

Altman Z-Score

-12.0

Lower score that deserves closer risk review.

FCF / Net Income

72.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Lucid Diagnostics Inc (NASDAQ-LUCD). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Lucid Diagnostics Inc (NASDAQ-LUCD)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

59

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Lucid Diagnostics Inc (NASDAQ-LUCD), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Lucid Diagnostics Inc (NASDAQ-LUCD) Stock Forecast & Technical Outlook

Review Lucid Diagnostics Inc (NASDAQ-LUCD) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Lucid Diagnostics Inc (NASDAQ-LUCD) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Lucid Diagnostics Inc (NASDAQ-LUCD) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Lucid Diagnostics Inc (NASDAQ-LUCD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Lucid Diagnostics Inc (NASDAQ-LUCD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Lucid Diagnostics Inc (NASDAQ-LUCD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Lucid Diagnostics Inc (NASDAQ-LUCD)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Lucid Diagnostics Inc (NASDAQ-LUCD) has a Strong Buy consensus, with 3 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 3
Hold 0
Sell 0
FAQ • Fast Investor Answers

Lucid Diagnostics Inc (NASDAQ-LUCD) Stock FAQ

Data-supported answers about Lucid Diagnostics Inc (NASDAQ-LUCD), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.74
Estimated downside 5.8%
Valuation Rating
Overvalued
Estimated downside of 5.8%
Analyst Target
$4
Implied upside 409.1%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Lucid Diagnostics Inc (NASDAQ-LUCD) is $0.74. This implies an estimated downside of 5.8% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 5.8% versus the current market price.

The available analyst price target for Lucid Diagnostics Inc (NASDAQ-LUCD) is $4. The analyst target implies estimated upside of 409.1%.

The current financial health read for Lucid Diagnostics Inc (NASDAQ-LUCD) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Lucid Diagnostics Inc (NASDAQ-LUCD) is November 16, 2026.

The latest available data indicates no current dividend yield for Lucid Diagnostics Inc (NASDAQ-LUCD).

The current market capitalization listed for Lucid Diagnostics Inc is 150 M.

The current enterprise value listed for Lucid Diagnostics Inc is 140.5 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Lucid Diagnostics Inc is NASDAQ-LUCD, and the stock is listed on NASDAQ.

Lucid Diagnostics Inc (NASDAQ-LUCD) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Lucid Diagnostics Inc is 14.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Lucid Diagnostics Inc is 73.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABT NYSE Abbott Laboratories Fair Value Fair Market Cap 177.6 B
ISRG NASDAQ Intuitive Surgical Inc Fair Value Fair Market Cap 139 B
MDT NYSE Medtronic PLC Fair Value Fair Market Cap 117.8 B
SYK NYSE Stryker Corporation Fair Value Fair Market Cap 105.5 B
BSX NYSE Boston Scientific Corp Fair Value Undervalued Market Cap 62.81 B
EW NYSE Edwards Lifesciences Corp Fair Value Fair Market Cap 50.873 B
BDX NYSE Becton Dickinson and Co Fair Value Undervalued Market Cap 49.286 B
MDLN NASDAQ Medline Inc Fair Value Fair Market Cap 41.807 B
IDXX NASDAQ IDEXX Laboratories Inc Fair Value Fair Market Cap 40.289 B
DXCM NASDAQ DexCom Inc Fair Value Fair Market Cap 33.717 B
RMD NYSE ResMed Inc Fair Value Undervalued Market Cap 32.188 B
ALC NYSE Alcon AG Fair Value Undervalued Market Cap 31.559 B
GEHC NASDAQ GE HealthCare Technologies Inc Fair Value Undervalued Market Cap 28.967 B
PHG NYSE Koninklijke Philips NV ADR Fair Value Undervalued Market Cap 24.25 B
STE NYSE STERIS plc Fair Value Undervalued Market Cap 19.991 B
ZBH NYSE Zimmer Biomet Holdings Inc Fair Value Undervalued Market Cap 18.189 B
SOLV NYSE Solventum Corp Fair Value Fair Market Cap 15.123 B
PEN NYSE Penumbra Inc Fair Value Fair Market Cap 12.51 B
BAX NYSE Baxter International Inc Fair Value Undervalued Market Cap 11.788 B
SNN NYSE Smith & Nephew SNATS Inc Fair Value Undervalued Market Cap 11.577 B